LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels
Author:
Affiliation:
1. Eli Lilly and Company; Indianapolis IN USA
2. Formerly of Lilly-NUS Centre for Clinical Pharmacology; Singapore Singapore
3. Formerly of Eli Lilly and Company; Indianapolis IN USA
4. Lilly-NUS Centre for Clinical Pharmacology; Singapore Singapore
Funder
Eli Lilly and Company
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science
Reference16 articles.
1. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml;Steinstraesser;Diabetes Obes Metab,2014
2. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus;Linnebjerg;Diabetes Obes Metab,2017
3. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies;Linnebjerg;Diabetes Care,2015
4. Human Insulin
5. European Medicines Agency Assessment report: Abasria 2014 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002835/WC500175383.pdf
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU‐ und US‐sourced reference insulins;Diabetes, Obesity and Metabolism;2023-09-21
2. Pharmacokinetics, Pharmacodynamics and Bioequivalence of Test Insulin Glargine versus Reference Preparation (Lantus®) in Healthy Male Volunteers—by Euglycemic Clamp Technique;2023-07-19
3. How to Achieve Sufficient Endogenous Insulin Suppression in Euglycemic Clamps Assessing the Pharmacokinetics and Pharmacodynamics of Long-Acting Insulin Preparations Employing Healthy Volunteers;Frontiers in Pharmacology;2022-07-22
4. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial;Diabetes Therapy;2022-04-26
5. Effects of Unsuppressed Endogenous Insulin on Pharmacokinetics and/or Pharmacodynamics of Study Insulin in the Healthy: A Retrospective Study;Clinical Pharmacology in Drug Development;2022-04-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3